Articles tagged with: Revlimid
Protein May Interfere With Revlimid Doses In The Body – Results of a recent small Phase 1 clinical trial investigating the efficacy and safety of Revlimid (lenalidomide) in combination with Torisel (temsirolimus) suggest that P-glycoprotein, a protein that causes the removal of certain drugs from cells into the bloodstream, interferes with Revlimid dosing. High levels of P-glycoprotein in cancer cells may be the cause of drug resistance. The researchers observed higher than expected concentrations of Revlimid in the patients’ bloodstreams. Experiments in the lab showed that P-glycoprotein removed Revlimid from the cancer cells. The experiments also showed that the rate of removal was lower when Torisel was added to the experiments, which, according to the study authors, is evidence that the two drugs interact via P-glycoprotein. For more information, please see the study in the Journal of Clinical Oncology (abstract) or the Ohio State University Medical Center press release.
Phase 2 Trial Of Carfilzomib For Multiple Myeloma Is Recruiting Patients – The Multiple Myeloma Clinical Research Section at the National Cancer Institute is recruiting participants for a Phase 2 trial to test the effectiveness of the investigational drug carfilzomib in combination with Revlimid and dexamethasone (Decadron) in newly-diagnosed multiple myeloma patients. Patients will receive eight 28-day treatment cycles. Those who show at least stable disease after the treatment may continue to receive 12 cycles of low-dose Revlimid maintenance therapy. In addition to current standard, clinical methods for determining responses to the drugs, the researchers will use new molecular methods to assess response and to detect minimal residual disease. To participate in the trial, please contact the research nurse, Mary Ann Yancey, at (301) 435-9227 or .
Chicago Area Workshop For Multiple Myeloma Patients – The Multiple Myeloma Research Foundation will hold a one-day educational workshop for myeloma patients and their family members on August 20 in Oak Brook, IL. The program will be led by Dr. Todd Zimmerman, a myeloma expert from the University of Chicago Medical Center. Throughout the day, myeloma experts will talk about treatments options for newly diagnosed and relapsed/refractory patients, including stem cell transplants, supportive care options, and clinical trials. The specialists will also be available to answer questions. Registration will begin at 9 a.m., and the program will last from 10 a.m. until 3:30 p.m. at the Hamburger University at the Hyatt Lodge. For more information or to register, please see the Multiple Myeloma Research Foundation website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
Novel agents, such as Velcade (bortezomib) and Revlimid (lenalidomide), have greatly advanced the treatment of patients with multiple myeloma. Indeed, by incorporating novel agents as induction therapy prior to consolidation with high-dose therapy and autologous stem cell transplantation, we have made huge strides in survival outcomes over the last 10 years. However, treatment with anti-myeloma agents may be associated with side effects that negatively impact quality of life.
Recently, two advances have been reported resulting in a decrease in peripheral neuropathy (nerve damage causing pain, numbness, and/or tingling …
The results of a recent Phase 2 trial show that the addition of cyclophosphamide to Revlimid and low-dose dexamethasone may result in better responses for previously untreated myeloma patients.
“This [study] provides the efficacy of another regimen for use in patients with myeloma,” said the study’s lead author Dr. Shaji Kumar of the Mayo Clinic in Rochester, Minnesota. “It is a fairly safe combination and is quite efficacious,” he stated in an e-mail to The Myeloma Beacon.
Italian researchers recently found that most myeloma patients are able to collect sufficient stem cells after a short course of induction therapy with Revlimid, allowing them to undergo two consecutive stem cell transplants.
“Revlimid can be used safely before stem cell mobilization, provided that we use only four courses before mobilization and cyclophosphamide is used to mobilize,” said Dr. Antonio Palumbo, lead author of the study and a researcher at the University of Torino in Italy.
The current standard treatment for younger patients with newly diagnosed myeloma includes induction therapy …
As the myeloma community continues to investigate whether stem cell transplantation or novel agents is the best way to treat newly diagnosed myeloma patients, recent results from a Phase 3 clinical trial indicate that stem cell transplantation may lead to longer disease-free survival.
The results from this study show that more multiple myeloma patients who received a stem cell transplant were alive and disease-free after 24 months compared to patients treated with Revlimid in combination with conventional chemotherapy.
The transplanted patients, however, also experienced more severe side effects compared to …